Impact of novel antifibrotic therapy on patient outcomes in idiopathic pulmonary fibrosis: patient selection and perspectives

References

• AhluwaliaNSheaBSTagerAMNew therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responsesAm J Respir Crit Care Med2014190886787825090037
   PubMed Web of Science ®Google Scholar
• RaghuGCollardHREganJJAn official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and managementAm J Respir Crit Care Med2011183678882421471066
   PubMed Web of Science ®Google Scholar
• OlsonALSwigrisJJLezotteDCNorrisJMWilsonCGBrownKKMortality from pulmonary fibrosis increased in the United States from 1992 to 2003Am J Respir Crit Care Med2007176327728417478620
   PubMed Web of Science ®Google Scholar
• YountSEBeaumontJLChenSYHealth-related quality of life in patients with idiopathic pulmonary fibrosisLung2016194222723426861885
   PubMed Web of Science ®Google Scholar
• TomiokaHImanakaKHashimotoKIwasakiHHealth-related quality of life in patients with idiopathic pulmonary fibrosis--cross-sectional and longitudinal studyIntern Med200746181533154217878639
   PubMed Web of Science ®Google Scholar
• van ManenMJGeelhoedJJTakNCWijsenbeekMSOptimizing quality of life in patients with idiopathic pulmonary fibrosisTher Adv Respir Dis201711315716928134007
   PubMed Web of Science ®Google Scholar
• OlsonALBrownKKSwigrisJJUnderstanding and optimizing health-related quality of life and physical functional capacity in idiopathic pulmonary fibrosisPatient Relat Outcome Meas20167293527274328
   PubMedGoogle Scholar
• SwigrisJJEsserDWilsonHPsychometric properties of the St George’s Respiratory Questionnaire in patients with idiopathic pulmonary fibrosisEur Respir J2017491160178828100551
   PubMed Web of Science ®Google Scholar
• SwigrisJJBrownKKBehrJThe SF-36 and SGRQ: validity and first look at minimum important differences in IPFRespir Med2010104229630419815403
   PubMed Web of Science ®Google Scholar
• SwigrisJJEsserDConoscentiCSBrownKKThe psychometric properties of the St George’s Respiratory Questionnaire (SGRQ) in patients with idiopathic pulmonary fibrosis: a literature reviewHealth Qual Life Outcomes20141212425138056
   PubMed Web of Science ®Google Scholar
• KreuterMSwigrisJPittrowDHealth related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registryRespir Res201718113928709421
   PubMed Web of Science ®Google Scholar
• SwigrisJJWilsonSRGreenKESprungerDBBrownKKWamboldtFSDevelopment of the ATAQ-IPF: a tool to assess quality of life in IPFHealth Qual Life Outcomes201087720673370
   PubMed Web of Science ®Google Scholar
• YorkeJSpencerLGDuckACross-Atlantic modification and validation of the A Tool to Assess Quality of Life in Idiopathic Pulmonary Fibrosis (ATAQ-IPF-cA)BMJ Open Respir Res201411e000024
   Google Scholar
• GraneyBJohnsonNEvansCJLiving with idiopathic pulmonary fibrosis (L-IPF): developing a patient-reported symptom and impact questionnaire to assess health-related quality of life in IPFAm J Respir Crit Care Med2017195A5353
   Web of Science ®Google Scholar
• PatelASSiegertRJKeirGJThe minimal important difference of the King’s Brief Interstitial Lung Disease Questionnaire (K-BILD) and forced vital capacity in interstitial lung diseaseRespir Med201310791438144323867809
   PubMed Web of Science ®Google Scholar
• PatelASSiegertRJBrignallKThe development and validation of the King’s Brief Interstitial Lung Disease (K-BILD) health status questionnaireThorax201267980481022555278
   PubMed Web of Science ®Google Scholar
• RicheldiLdu BoisRMRaghuGEfficacy and safety of nintedanib in idiopathic pulmonary fibrosisN Engl J Med2014370222071208224836310
   PubMed Web of Science ®Google Scholar
• KingTEBradfordWZCastro-BernardiniSA phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosisN Engl J Med2014370222083209224836312
   PubMed Web of Science ®Google Scholar
• TaniguchiHEbinaMKondohYPirfenidone in idiopathic pulmonary fibrosisEur Respir J201035482182919996196
   PubMed Web of Science ®Google Scholar
• NoblePWAlberaCBradfordWZPirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trialsLancet201137797791760176921571362
   PubMed Web of Science ®Google Scholar
• GeorgeGVaidUSummerRTherapeutic advances in idiopathic pulmonary fibrosisClin Pharmacol Ther2016991303226502087
   PubMed Web of Science ®Google Scholar
• RicheldiLCostabelUSelmanMEfficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosisN Engl J Med2011365121079108721992121
   PubMed Web of Science ®Google Scholar
• RicheldiLCottinVdu BoisRMNintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS(®) trialsRespir Med2016113747926915984
   PubMed Web of Science ®Google Scholar
• KimESKeatingGMPirfenidone: a review of its use in idiopathic pulmonary fibrosisDrugs201575221923025604027
   PubMed Web of Science ®Google Scholar
• NoblePWAlberaCBradfordWZPirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trialsEur Respir J201647124325326647432
   PubMed Web of Science ®Google Scholar
• LeyBSwigrisJDayBMPirfenidone reduces respiratory-related hospitalizations in idiopathic pulmonary fibrosisAm J Respir Crit Care Med2017196675676128471697
   PubMed Web of Science ®Google Scholar
• NathanSDAlberaCBradfordWZEffect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosisThorax201671542943526968970
   PubMed Web of Science ®Google Scholar
• EakinEGResnikoffPMPrewittLMRiesALKaplanRMValidation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. University of California, San DiegoChest199811336196249515834
   PubMed Web of Science ®Google Scholar
• SwigrisJJGouldMKWilsonSRHealth-related quality of life among patients with idiopathic pulmonary fibrosisChest2005127128429415653996
   PubMed Web of Science ®Google Scholar
• van ManenMJGBirringSSVancheriCEffect of pirfenidone on cough in patients with idiopathic pulmonary fibrosisEur Respir J2017504170115729051272
   PubMed Web of Science ®Google Scholar
• NishiyamaOTaniguchiHKondohYHealth-related quality of life in patients with idiopathic pulmonary fibrosis. What is the main contributing factor?Respir Med200599440841415763446
   PubMed Web of Science ®Google Scholar
• BelkinASwigrisJJHealth-related quality of life in idiopathic pulmonary fibrosis: where are we now?Curr Opin Pulm Med201319547447923851327
   PubMed Web of Science ®Google Scholar
• GraneyBAWamboldtFSBairdSLooking ahead and behind at supplemental oxygen: a qualitative study of patients with pulmonary fibrosisHeart Lung201746538739328774655
   PubMed Web of Science ®Google Scholar
• NiciLDonnerCWoutersEAmerican Thoracic Society/European Respiratory Society statement on pulmonary rehabilitationAm J Respir Crit Care Med2006173121390141316760357
   PubMed Web of Science ®Google Scholar
• NishiyamaOKondohYKimuraTEffects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosisRespirology200813339439918399862
   PubMed Web of Science ®Google Scholar
• HollandAEHillCJConronMMunroPMcdonaldCFShort term improvement in exercise capacity and symptoms following exercise training in interstitial lung diseaseThorax200863654955418245143
   PubMed Web of Science ®Google Scholar
• SwigrisJJFaircloughDLMorrisonMBenefits of pulmonary rehabilitation in idiopathic pulmonary fibrosisRespir Care201156678378921333082
   PubMed Web of Science ®Google Scholar
• OzalevliSKaraaliHKIlginDUcanESEffect of home-based pulmonary rehabilitation in patients with idiopathic pulmonary fibrosisMultidiscip Respir Med201051313722958625
   PubMed Web of Science ®Google Scholar
• KozuRSenjyuHJenkinsSCMukaeHSakamotoNKohnoSDifferences in response to pulmonary rehabilitation in idiopathic pulmonary fibrosis and chronic obstructive pulmonary diseaseRespiration201181319620520516666
   PubMed Web of Science ®Google Scholar
• DowmanLHillCJHollandAEPulmonary rehabilitation for interstitial lung diseaseCochrane Database Syst Rev201410CD006322
   PubMed Web of Science ®Google Scholar
• Idiopathic Pulmonary Fibrosis Clinical Research NetworkZismanDASchwarzMA controlled trial of sildenafil in advanced idiopathic pulmonary fibrosisN Engl J Med2010363762062820484178
   PubMed Web of Science ®Google Scholar
• RaghuGRochwergBZhangYAn Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice GuidelineAm J Respir Crit Care Med20151922e3e1926177183
   PubMed Web of Science ®Google Scholar
• LamasDJKawutSMBagiellaEPhilipNArcasoySMLedererDJDelayed access and survival in idiopathic pulmonary fibrosis: a cohort studyAm J Respir Crit Care Med2011184784284721719755
   PubMed Web of Science ®Google Scholar
• RaghuGAmattoVCBehrJStowasserSComorbidities in idiopathic pulmonary fibrosis patients: a systematic literature reviewEur Respir J20154641113113026424523
   PubMed Web of Science ®Google Scholar
• SwigrisJJStewartALGouldMKWilsonSRPatients’ perspectives on how idiopathic pulmonary fibrosis affects the quality of their livesHealth Qual Life Outcomes200536116212668
   PubMedGoogle Scholar
• van ManenMJBirringSSVancheriCCough in idiopathic pulmonary fibrosisEur Respir Rev20162514127828627581827
   PubMed Web of Science ®Google Scholar
• RyersonCJCayouCToppFPulmonary rehabilitation improves long-term outcomes in interstitial lung disease: a prospective cohort studyRespir Med2014108120321024332409
   PubMed Web of Science ®Google Scholar
• CaoMWamboldtFSBrownKKSupplemental oxygen users with pulmonary fibrosis perceive greater dyspnea than oxygen non-usersMultidiscip Respir Med2015103726693009
   PubMedGoogle Scholar
• NishiyamaOTaniguchiHKondohYA simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosisEur Respir J20103651067107220413545
   PubMed Web of Science ®Google Scholar
• BelkinAAlbrightKSwigrisJJA qualitative study of informal caregivers’ perspectives on the effects of idiopathic pulmonary fibrosisBMJ Open Respir Res201411e000007
   Google Scholar
• GraneyBAWamboldtFSBairdSInformal caregivers experience of supplemental oxygen in pulmonary fibrosisHealth Qual Life Outcomes201715113328668090
   PubMed Web of Science ®Google Scholar
• CullenDLStifflerDLong-term oxygen therapy: review from the patients’ perspectiveChron Respir Dis20096314114719643828
   PubMedGoogle Scholar
• HortonMRSantopietroVMathewLThalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trialAnn Intern Med2012157639840622986377
   PubMed Web of Science ®Google Scholar
• BirringSSWijsenbeekMSAgrawalSA novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trialLancet Respir Med201751080681528923239
   PubMed Web of Science ®Google Scholar
• LancasterLHMasonWRParnellJAObstructive sleep apnea is common in idiopathic pulmonary fibrosisChest2009136377277819567497
   PubMed Web of Science ®Google Scholar
• MermigkisCBouloukakiIAntoniouKObstructive sleep apnea should be treated in patients with idiopathic pulmonary fibrosisSleep Breath201519138539125028171
   PubMed Web of Science ®Google Scholar
• KingCSNathanSDIdiopathic pulmonary fibrosis: effects and optimal management of comorbiditiesLancet Respir Med201751728427599614
   PubMed Web of Science ®Google Scholar
• BellECCoxNSGohNOxygen therapy for interstitial lung disease: a systematic reviewEur Respir Rev20172614316008028223395
   PubMed Web of Science ®Google Scholar
• ViscaDMontgomeryAde LauretisAAmbulatory oxygen in interstitial lung diseaseEur Respir J201138498799021965506
   PubMed Web of Science ®Google Scholar
• NajiNAConnorMCDonnellySCMcdonnellTJEffectiveness of pulmonary rehabilitation in restrictive lung diseaseJ Cardiopulm Rehabil200626423724316926688
   PubMedGoogle Scholar